ImmuPharma (25I) Stock Statistics & Valuation Metrics
Total Valuation
ImmuPharma has a market cap or net worth of EUR 24.30M. The enterprise value is EUR 20.22M.
- Market Cap
- EUR 24.30M
- Enterprise Value
- EUR 20.22M
Share Statistics
ImmuPharma has 623,911,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 623,911,400
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
ImmuPharma’s return on equity (ROE) is -2.63 and return on invested capital (ROIC) is -308.07%.
- Return on Equity (ROE)
- -2.63
- Return on Assets (ROA)
- -0.96
- Return on Invested Capital (ROIC)
- -308.07%
- Return on Capital Employed (ROCE)
- -3.70
- Revenue Per Employee
- 0
- Profits Per Employee
- -258.24K
- Employee Count
- 7
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ImmuPharma is -2.60. ImmuPharma’s PEG ratio is 0.02.
- PE Ratio
- -2.60
- PS Ratio
- 0.00
- PB Ratio
- 9.97
- Price to FCF
- -7.33
- Price to Operating Cash Flow
- -6.58
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, ImmuPharma had revenue of 0 and earned -1.81M in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- -35.30K
- Operating Income
- -2.54M
- Pretax Income
- -2.17M
- Net Income
- -1.81M
- EBITDA
- -2.51M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -2.76M and capital expenditures -3,632, giving a free cash flow of -2.77M billion.
- Operating Cash Flow
- -2.76M
- Free Cash Flow
- -2.77M
- Free Cash Flow per Share
- -0.00
Dividends & Yields
ImmuPharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -13.65%
- Earnings Yield
- -38.64%
Stock Price Statistics
- Beta
- 6.97
- 52-Week Price Change
- -82.24%
- 50-Day Moving Average
- 0.03
- 200-Day Moving Average
- 0.04
- Relative Strength Index (RSI)
- 43.92
- Average Volume (3m)
- 16.25K
Important Dates
ImmuPharma upcoming earnings date is May 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 15, 2026
- Next Earnings Date
- May 25, 2027
- Ex-Dividend Date
- ―
Financial Position
ImmuPharma as a current ratio of 1.52, with Debt / Equity ratio of 0.00%
- Current Ratio
- 1.52
- Quick Ratio
- 1.52
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.54
- Interest Coverage Ratio
- -214.45
Taxes
In the past 12 months, ImmuPharma has paid -364.50K in taxes.
- Income Tax
- -364.50K
- Effective Tax Rate
- 0.17
Enterprise Valuation
ImmuPharma EV to EBITDA ratio is -5.52, with an EV/FCF ratio of -7.07.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.52
- EV to Free Cash Flow
- -7.07
- EV to Operating Cash Flow
- -7.08
Balance Sheet
ImmuPharma has EUR 695.84K in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 695.84K billion.
- Cash & Marketable Securities
- EUR 695.84K
- Total Debt
- EUR 0.00
- Net Cash
- EUR 695.84K
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for ImmuPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 8.57%
